drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous T cells engineered to express a tri-specific chimeric antigen receptor targeting CD19, CD20, and CD22; CAR engagement triggers CD3ΞΆ signaling, T-cell activation, cytokine release, and cytotoxic killing to eliminate malignant B cells and reduce antigen escape.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a tri-specific CAR targeting CD19, CD20, and CD22; antigen binding triggers CD3zeta and costimulatory signaling to activate the T cell, leading to cytokine release and perforin/granzyme-mediated cytotoxic killing of malignant B cells, with multi-antigen targeting designed to reduce antigen escape.
drug_name
CD19.20.22 CAR T cells
nct_id_drug_ref
NCT07168486